Benralizumab

證據等級: L5

預測適應症: 5 個

Benralizumab: From Severe Eosinophilic Asthma to Atopic Dermatitis

One-Sentence Summary

Benralizumab is an anti-IL-5Rα monoclonal antibody that depletes eosinophils, with established clinical use in severe eosinophilic asthma (per trial/literature context in this evidence pack — the drug is not marketed in Norway and no regulatory indication text is on file). TxGNN's top-ranked prediction (immune thrombocytopenia) has no supporting trials or literature, so this report focuses on Atopic Dermatitis, the only candidate with substantial real-world clinical evidence — 6 clinical trials and 20 publications. However, the key confirmatory Phase 2 RCT (HILLIER) was terminated early and published as a negative result, so the evidence currently argues against, not for, this repurposing direction.

Quick Overview

Item	Content
Original Indication	Not specified in Norway regulatory data (drug not marketed); evidence context indicates severe eosinophilic asthma
Predicted New Indication	Atopic Dermatitis (TxGNN label: "dermatitis")
TxGNN Prediction Score	99.16% (rank 8215)
Evidence Level	L2 (1 completed Phase 2 trial exists), but the larger confirmatory Phase 2 RCT was terminated with a negative efficacy outcome
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for benralizumab is not available in this evidence pack (Data Gap DG002). Based on the literature retrieved, benralizumab binds IL-5Rα and depletes eosinophils via antibody-dependent cell-mediated cytotoxicity — this is the mechanism underlying its use in severe eosinophilic asthma. Atopic dermatitis lesions also show tissue eosinophilia, which is the mechanistic rationale TxGNN's knowledge graph likely leveraged to link the two conditions.

Clinically, however, this hypothesis has already been tested: a dedicated Phase 2 RCT (NCT04605094, "HILLIER," N=194) was designed specifically to test benralizumab in moderate-to-severe atopic dermatitis. The trial was terminated early, and the published result (PMID 37178404) is titled "Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis." The literature consistently frames dupilumab (anti-IL-4/13) — not anti-IL-5 agents — as the effective biologic class for AD, suggesting eosinophils are not the primary pathogenic driver in this disease, unlike in eosinophilic asthma. This is a case where TxGNN's mechanistic plausibility did not translate into clinical benefit.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03563066	Phase 2	Completed	20	Small mechanistic study on eosinophil/basophil/ILC2 effects of benralizumab in AD skin.
NCT04605094	Phase 2	Terminated	194	Pivotal placebo-controlled AD trial ("HILLIER"); published result shows no significant clinical benefit — key negative finding for this repurposing candidate.
NCT04126499	N/A	Completed	28	Observational cohort of severe eosinophilic asthma patients receiving benralizumab; not AD-specific.
NCT04763447	Phase 4	Recruiting	234	Omalizumab (not benralizumab) withdrawal trial in severe asthma; of limited direct relevance.
NCT06734884	Phase 2	Not yet recruiting	96	Anti-IL-5Rα therapy in DRESS syndrome — a different eosinophil-driven skin/systemic reaction, not AD.
NCT06477653	Phase 2	Recruiting	30	Dupilumab add-on for hypereosinophilic syndrome in patients with partial response to eosinophil-depleting biologics (incl. benralizumab); background use only.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37178404	2023	RCT	J Eur Acad Dermatol Venereol	Full HILLIER trial results: benralizumab showed no effect on AD signs/symptoms vs placebo.
38695680	2024	Plain-language summary	Immunotherapy	Patient-friendly summary of the same negative HILLIER trial.
36270814	2023	Case report	Therapie	Reports benralizumab-induced interstitial granulomatous dermatitis — an adverse skin reaction, not a therapeutic benefit.
38074921	2024	Case series	Respirology Case Reports	Dual-biologic (dupilumab + mepolizumab/benralizumab/tezepelumab) use in severe asthma with AD comorbidity; benralizumab used as asthma add-on, not primary AD treatment.
31690400	2019	Review	Allergy Asthma Proc	Reviews immunobiologics (anti-IgE, anti-IL-5, anti-IL-4/13) across asthma, AD, urticaria; positions benralizumab primarily as an anti-IL-5 asthma agent.
33717370	2020	Real-world experience	Open Respir Med J	Real-life biologic use across urticaria, asthma, and AD in UAE cohort.
39600395	2024	Review	Allergologie Select	Update on biologics for atopic disease/urticaria/angioedema, contextualizing anti-IL-5 vs anti-IL-4/13 classes.
36355314	2023	Review	Dermatol Ther	Discusses combining dupilumab with other monoclonal antibodies (incl. anti-IL-5 agents) for comorbid conditions.
33138725	2021	Review	Otolaryngol Head Neck Surg	Reviews targeted biologics across Type 2 inflammatory conditions including AD.
38878020	2024	Cohort study	J Allergy Clin Immunol	Patients on benralizumab/dupilumab/mepolizumab show lower post-vaccination SARS-CoV-2 immunity — relevant safety signal, not AD-specific.

Norway Market Information

Benralizumab has no marketing authorizations on file for Norway (market_status: 未上市 / Not marketed; total_licenses: 0). No licence-level indication text is available to summarize.

Safety Considerations

Please refer to the package insert for safety information. Formal warnings, contraindications, and DDI data are not available in the current dataset (Data Gap DG001, marked Blocking).

Additional signals identified from the literature evidence (not part of the structured safety dataset):

A case report of benralizumab-induced interstitial granulomatous dermatitis (PMID 36270814) — paradoxically, a skin adverse reaction rather than benefit.
Reduced post-vaccination SARS-CoV-2 antibody response in patients on benralizumab (PMID 38878020), relevant to vaccination timing counseling.

Other Candidate Indications for This Drug (Portfolio Overview)

For context, this evidence pack included four other TxGNN-predicted indications for benralizumab, none of which currently have supporting evidence:

Rank	Disease	TxGNN Score	Evidence	Recommendation
1	Thrombocytopenia due to immune destruction	99.34%	None (no trials/literature)	Hold (L5, model-only)
3	Acne keloid	99.13%	None (no trials/literature)	Hold (L5, model-only)
4	Neonatal dermatomyositis	99.05%	None; mechanism mismatch (maternal antibody/IFN-I driven, not eosinophilic)	Hold (L5/S0)
5	Amyopathic dermatomyositis	99.03%	None; mechanism mismatch (IFN-I/complement driven, not eosinophilic)	Hold (L5/S0)

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistically plausible candidate (atopic dermatitis) has already been tested in an adequately sized Phase 2 RCT (HILLIER, N=194), which was terminated early and published as a negative result. TxGNN's other top-ranked candidates for this drug have no supporting clinical or literature evidence at all (L5). Combined with the drug's lack of Norway market presence and unavailable formal safety/label data, there is currently no viable repurposing pathway to advance.

To proceed, the following is needed:

TFDA/manufacturer package insert (warnings, contraindications) — currently Blocking gap (DG001)
DrugBank-sourced MOA confirmation (DG002)
Monitor the emerging DRESS (NCT06734884) and hypereosinophilic syndrome (NCT06477653) trials — these represent mechanistically better-aligned eosinophil-driven conditions than AD, and may surface as stronger candidates once results mature
No further investment recommended in atopic dermatitis given the existing negative RCT
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.